MTCL1

Across TCGA pan-cancer cohorts, MTCL1 Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated MTCL1 data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher MTCL1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated MTCL1 expression acts as an unfavorable survival marker, although some lineages such as UCEC and STAD show a favorable association.

LUSC, UCEC, and BRCA are the cancer types where MTCL1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	DFS	Median	II,III,IV	0.079	0.750	<.001	27	view →
UCEC	DFS	Median	II,III,IV	0.937	0.435	.016	26	view →
BRCA	OS	Median	III,IV	0.131	0.833	<.001	12	view →
LGG	OS	Median	All	0.589	0.896	<.001	10	view →
PRAD	DFS	Median	All	0.187	0.777	.004	4	view →
COAD	OS	Median	II,III,IV	0.263	0.689	.011	4	view →
SCLC	OS	Median	II,III,IV	0.152	0.777	.038	3	view →
STAD	OS	Median	III,IV	0.786	0.359	.047	2	view →
LUAD	OS	Median	All	0.624	0.838	.030	1	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

MTCL1–LUSC (DFS)

Open the LUSC breakdown →